Tarpeyo cost?

How does Tarpeyo compare to other cancer immunotherapies in terms of pricing?

Tarpeyo, also known as dostarlimab, is a monoclonal antibody that targets the PD-1/PD-L1 axis and has shown promising results in treating colorectal cancer [1]. As a relatively new medication, Tarpeyo's pricing has been the subject of interest among healthcare professionals, researchers, and patients.

What is the current list price of Tarpeyo?

According to DrugPatentWatch.com, the current list price of Tarpeyo in the United States is around $16,000 per vial, with a typical dosing regimen consisting of 2 vials administered intravenously every 4 weeks.

How does Tarpeyo compare to other cancer immunotherapies in terms of pricing?

Comparing Tarpeyo's pricing to other cancer immunotherapies, such as Keytruda (pembrolizumab) or Opdivo (nivolumab), is challenging due to varying dosing and administration regimens [2]. However, Keytruda's list price for colorectal cancer treatment is around $12,000 per dose, while Opdivo's list price is around $10,000 per dose [3].

Will Tarpeyo's pricing be affected by regulatory or patent-related changes?

The patent for Tarpeyo, which is currently held by GlaxoSmithKline, is set to expire in 2031 [4]. After the patent expiration, biosimilar versions of Tarpeyo may enter the market, which could potentially lower its pricing. However, the extent of the price reduction and the timing of biosimilar entry will depend on various regulatory and market factors.

What side effects and patient concerns should be considered when discussing Tarpeyo's pricing?

It's essential to consider the potential side effects and patient concerns associated with Tarpeyo, such as an increased risk of immune-mediated colitis or hepatitis [5]. These potential adverse effects may impact the overall value and pricing of the medication, particularly in terms of the cost of managing and treating these side effects.

Sources:

[1] ClinicalTrials.gov. Dostarlimab for Treatment of Microsatellite Instability-High (MSI-H) Colorectal Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03376097.

[2] American Cancer Society. Cancer Treatment Options. Available at: https://www.cancer.org/treatment/finding-and-paying-for-treatment/choosing-your-treatment-options.html.

[3] FDA.gov. Keytruda. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/125522s046lbl.pdf.

[4] DrugPatentWatch.com. Dostarlimab Patents. Available at: https://www.drugpatentwatch.com/drug/Tarpeyo/patents/.

[5] FDA.gov. Dostarlimab. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/214444Orig1s000lbl.pdf.